Integrase is an enzyme produced by retroviruses, most famously HIV, that stitches the virus’s genetic material into the DNA of the host cell. Without it, the virus cannot establish a permanent foothold. This single protein carries out a remarkable feat of molecular surgery: it cuts the host’s chromosome, inserts a copy of the viral genome, and relies on the cell’s own repair machinery to seal the joins. Integrase has become one of the most important drug targets in modern HIV treatment, and its cousins show up across biology in contexts that have nothing to do with disease.
What Integrase Actually Does, Step by Step
Before a retrovirus can hijack a cell, it first converts its RNA genome into double-stranded DNA using reverse transcriptase. Integrase takes over from there. Its job unfolds in two distinct chemical reactions, both of which amount to cutting and re-joining DNA strands.
In the first step, called 3′ processing, integrase trims a short stretch of nucleotides from each end of the viral DNA. A water molecule acts as the chemical scissors, snipping the strand to expose a reactive hydroxyl group attached to a conserved two-letter genetic sequence (CA) found at both viral DNA ends.1PubMed Central. 3′-processing and strand transfer catalysed by retroviral integrase in crystallo Those freshly exposed ends are the business ends of the molecule: they will do the actual attacking in the next step.
In the second step, strand transfer, the exposed viral DNA ends act as chemical projectiles. Each one attacks a phosphate bond on opposite strands of the host’s chromosomal DNA, separated by a few base pairs. The viral DNA ends up covalently joined to the host chromosome in a single concerted reaction.2PubMed Central. Retroviral Integrase Structure and DNA Recombination Mechanism Both reactions, 3′ processing and strand transfer, work by the same underlying chemistry: a nucleophile attacks a phosphate bond and swaps in, a process researchers call direct transesterification. The difference is just which nucleophile does the job.
After strand transfer, the work is not quite done. The insertion leaves small gaps and mismatched flaps at each junction between viral and host DNA. Integrase cannot fix those itself. Instead, host cell DNA repair enzymes fill the gaps, trim the overhangs, and ligate the remaining nicks. Studies have identified at least three types of activity needed to finish the job: a DNA polymerase to fill in missing bases, a nuclease to clip the flap, and a ligase to seal the final nicks.3PubMed Central. Repair of gaps in retroviral DNA integration intermediates The host’s own DNA damage-response pathway also plays a role. Integrase physically binds a protein called Ku70, which recruits a repair complex to the integration site, helping clean up the molecular aftermath.4PubMed Central. NHEJ pathway is involved in post-integrational DNA repair due to Ku70 binding to HIV-1 integrase
The Three-Part Structure
HIV integrase is a relatively compact protein, just 288 amino acids long, divided into three structural domains that each handle a different part of the integration process.5PubMed. HIV integrase structure and function
The central catalytic core domain (roughly residues 50 through 212) is where the chemistry happens. It contains a trio of acidic amino acids, two aspartates and one glutamate, that coordinate metal ions and carry out both cutting and joining reactions.6PubMed. Three new structures of the core domain of HIV-1 integrase: an active site that binds magnesium The fold of this domain is shared with other enzymes that move DNA around, including a bacterial transposase and an enzyme called RNase H that degrades RNA in DNA-RNA hybrids. That family resemblance is a clue to an ancient evolutionary connection.
The small N-terminal domain sits at the front of the protein and folds into a compact structure stabilized by a zinc ion. It helps integrase molecules assemble into larger functional units, promoting the formation of the tetramers and higher-order complexes needed for activity. The C-terminal domain, at the opposite end, handles DNA binding. When two copies of this domain come together, they form a broad saddle-shaped cleft that grips the DNA.7PubMed Central. Structure of a two-domain fragment of HIV-1 integrase: implications for domain organization in the intact protein
The Intasome and Its Surprising Complexity
Integrase does not work alone or as a single copy. It assembles into a large molecular machine called the intasome: a complex of multiple integrase molecules bound to the ends of viral DNA. For HIV, the minimal functional unit is a tetramer (four copies of integrase), and higher-order forms with additional subunits also exist.8PubMed Central. Cryo-EM structures and atomic model of the HIV-1 strand transfer complex intasome The intasome is what actually carries out the coordinated insertion of both viral DNA ends into the host chromosome at the same time.
Different retroviruses build their intasomes in different ways. A study of mouse mammary tumour virus revealed an octameric intasome, meaning eight copies of integrase assemble into the active complex. Four of those copies form a central catalytic core that resembles the HIV tetramer, while the other four form flanking dimers that stabilize the structure and turn out to be essential for activity.9PubMed Central. Cryo-EM reveals a novel octameric integrase structure for betaretroviral intasome function That finding overturned the assumption that four copies of integrase were always enough. The architecture of the intasome, in other words, varies across retroviral families, even though the core catalytic mechanism is conserved.
How HIV Picks Where to Insert Its DNA
Integration is not random. HIV strongly favors inserting its DNA into genes that are actively being read by the cell, and the virus achieves this targeting largely through a single host protein called LEDGF/p75. LEDGF acts as a molecular tether: one part of it grabs onto integrase, and another part grabs onto a chemical mark on chromosomal proteins (a specific modification on histone H3 associated with active transcription).10Nucleic Acids Research. Molecular mechanisms of retroviral integration site selection The result is that LEDGF steers the integration machinery toward genes the cell is actively using.
When researchers depleted cells of LEDGF, integration became less frequent inside genes, shifted away from genes regulated by LEDGF itself, and showed up more often in GC-rich DNA regions that LEDGF does not target.11PubMed. An essential role for LEDGF/p75 in HIV integration LEDGF also directs integration toward the 5′ end of genes; in cells lacking the protein, that bias disappears.12Genes & Development. LEDGF/p75 interacts with mRNA splicing factors and targets HIV-1 integration to highly spliced genes
Beyond LEDGF, the physical folding of chromosomes in three dimensions also plays a role. Computational modeling combined with experimental data suggests that regions of the genome that are loosely packed and accessible, a hallmark of active chromatin, are inherently more likely to be hit by integration simply because they take up more space and present more surface area.13Nature Communications. Physical principles of retroviral integration in the human genome So the targeting of active genes is driven by at least two forces: a protein-level tether and a physical-geometry bias.
Other retroviruses use different host proteins to achieve different targeting. Murine leukemia virus, for example, preferentially inserts near the starts of genes and near proto-oncogenes. It relies on host BET proteins that recognize a distinct set of histone modifications enriched in those regions.10Nucleic Acids Research. Molecular mechanisms of retroviral integration site selection Each virus-host pairing has its own targeting logic, which has real consequences for disease: insertion near an oncogene can activate it and drive cancer, a problem that has complicated gene therapy approaches using retroviral vectors.
Integrase as a Drug Target
Because integrase has no close equivalent in human cells, it makes an attractive target for antiviral drugs. The most successful class of HIV drugs aimed at integrase are the integrase strand transfer inhibitors, or INSTIs. As the name implies, they block the second step of integration, strand transfer, by binding to the active site when it is loaded with metal ions and viral DNA. Drugs in this class, including dolutegravir and bictegravir, are now front-line treatments for HIV and are among the most effective antiretrovirals available.14PubMed Central. Mechanisms of HIV-1 integrase resistance to dolutegravir and potent inhibition of drug-resistant variants
A separate class of experimental drugs, called allosteric integrase inhibitors (ALLINIs), takes a different approach. Rather than plugging the active site, these compounds latch onto the surface where LEDGF normally binds. They do several things at once: they block the LEDGF–integrase interaction, they lock integrase into an inactive clumped-up form, and they prevent the proper assembly of integrase with viral DNA.15PubMed Central. Multimode, cooperative mechanism of action of allosteric HIV-1 integrase inhibitors Interestingly, the most potent effects of ALLINIs occur not during integration itself but during the assembly of new virus particles. ALLINIs cause integrase to clump abnormally inside budding virions, preventing the formation of a proper viral core and crippling the virus before it even reaches its next target cell.16PubMed Central. Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation
Drug Resistance and the Barrier to Escape
HIV mutates rapidly, so resistance to any single drug is always a concern. The newer INSTIs have a remarkably high barrier to resistance compared with earlier drugs in the class. Earlier inhibitors like elvitegravir could be defeated by a handful of mutations that appeared within weeks in lab selection experiments, eventually conferring resistance levels above 100-fold.17PubMed Central. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir By contrast, dolutegravir and bictegravir selections in the same experiments typically produced only single mutations conferring low-level resistance of less than three-fold. Bictegravir retained activity even against a dual-mutation variant, which showed only about a three-fold reduction in susceptibility.18PubMed Central. Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile
Resistance becomes clinically meaningful when multiple mutations stack up, particularly combinations involving changes at position 148 in the integrase sequence along with secondary mutations elsewhere. Structural studies show that these combinations alter the geometry of the active site enough to weaken drug binding while still allowing the enzyme to function, though typically at reduced efficiency.14PubMed Central. Mechanisms of HIV-1 integrase resistance to dolutegravir and potent inhibition of drug-resistant variants Researchers are using these structural insights to design next-generation inhibitors that maintain potency against resistant variants.
Integrase Has a Second Job During Virus Assembly
For decades, integrase was understood as a one-trick enzyme: it inserted DNA. But research over the past fifteen years has shown that HIV integrase also plays a structural role during the assembly and maturation of new virus particles. Viruses produced in the presence of non-catalytic-site integrase inhibitors (NCINIs) processed their other proteins normally and had functional reverse transcriptase, but their internal core structures were grossly abnormal. These defective particles could not initiate DNA synthesis after entering a new cell.19PubMed Central. Non-catalytic site HIV-1 integrase inhibitors disrupt core maturation and induce a reverse transcription block in target cells
This means integrase is not just an enzyme that acts once inside the nucleus and then becomes irrelevant. It has a second life as a structural component during the late phase of the viral life cycle. Disrupting that role, even without touching the catalytic active site, can cripple the virus. This discovery opened an entirely new avenue for drug development, since compounds targeting integrase’s assembly function hit the virus at a stage and through a mechanism distinct from traditional INSTIs.
Integrases Beyond Retroviruses
Retroviral integrase is one member of a much larger family. Bacterial viruses (bacteriophages) produce their own integrases that insert phage DNA into the bacterial chromosome, but the machinery is fundamentally different. Phage integrases fall into two major families based on the amino acid they use to cut DNA. Tyrosine recombinases, like the famous lambda integrase from phage lambda, use a tyrosine residue to break and rejoin DNA strands, recognize relatively long attachment sequences, and often need additional host-encoded helper proteins. Serine recombinases are larger, use a serine residue for catalysis, work on shorter recognition sequences, and tend to function without host cofactors.
Retroviral integrases, by contrast, belong to a different enzyme superfamily entirely, characterized by a conserved trio of acidic residues (DDE) in their active site. This DDE motif links retroviral integrases to DNA transposases found in mobile genetic elements across all domains of life. Phylogenetic analyses suggest these enzymes share a common ancestor.20PubMed. Do the integrases of LTR-retrotransposons and class II element transposases have a common ancestor? The chemical mechanism, cutting and joining DNA using metal-ion-dependent transesterification, is ancient and has been repurposed many times by evolution for various genome-rearranging tasks.
An intriguing hint of just how far this enzyme family has spread comes from the mammalian genome itself. A gene called Gin-1, found in humans and other mammals, encodes a protein whose sequence is unmistakably derived from the integrase domain of a particular family of retrotransposons. Phylogenetic analysis traces its origin to a time before the split between protostomes and deuterostomes, meaning these transposable elements were already present in animal genomes over half a billion years ago.21Molecular Biology and Evolution. A Mammalian Gene Evolved from the Integrase Domain of an LTR Retrotransposon What Gin-1 does in mammals today, if anything, remains an open question, but its existence shows that integrase-like sequences can be repurposed by the host.
Endogenous Retroviruses and the Human Genome
When a retrovirus integrates into a cell that happens to produce eggs or sperm, the inserted viral DNA can be inherited by the next generation. Over millions of years, this process has seeded the human genome with remnants of ancient retroviruses, collectively called endogenous retroviruses (ERVs). Roughly eight percent of the human genome is made up of ERV sequences, the accumulated legacy of integrase activity over evolutionary time.22PubMed. The evolutionary dynamics of human endogenous retroviral families The vast majority of these sequences have been disabled by mutations and deletions, but fragments of them continue to influence gene regulation, immune function, and other aspects of human biology in ways researchers are still uncovering.
There is even functional overlap between retroviral integrase and the immune system’s own DNA-cutting machinery. The RAG1/2 recombinase, which rearranges antibody and T-cell receptor genes during immune-cell development, uses a DNA-cutting mechanism with striking similarities to integrase and transposase enzymes. HIV integrase inhibitors of the diketo acid type can interfere with some RAG1/2 activities in laboratory assays, underscoring how closely related the chemistry is.23PubMed Central. Effect of HIV integrase inhibitors on the RAG1/2 recombinase In practice, the clinical doses of integrase inhibitors used to treat HIV do not appear to cause immune-development problems in patients, but the enzymatic kinship between integrase and RAG is a vivid reminder of shared evolutionary origins.
Putting a Broken Integrase to Work in Gene Therapy
Integration is a double-edged sword for gene therapy. On one hand, inserting a therapeutic gene permanently into a patient’s genome means the correction lasts the life of the cell. On the other, uncontrolled insertion near a cancer-promoting gene can cause leukemia, a real problem that derailed early retroviral gene therapy trials. One way to thread this needle is to use integrase deliberately crippled by mutation.
Researchers have engineered lentiviral vectors (based on the HIV backbone) carrying an integrase with a specific mutation that reduces its integration activity by a factor of 500 to over 1,000 compared with the normal enzyme. These vectors can still deliver a gene into both dividing and non-dividing cells, but the delivered DNA stays as a free-floating circle in the nucleus rather than stitching itself into the chromosome. In dividing cells, expression is transient because the circles get diluted as cells split. In non-dividing cells, like neurons, the circles persist and the gene stays active for extended periods.24PubMed Central. Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo When injected into mouse brains, these integrase-defective vectors drove gene expression in brain cells, demonstrating their potential for applications where permanent integration is unnecessary or undesirable, such as delivering a vaccine antigen or providing temporary expression of a protein while tissue heals.
This approach reframes integrase from a purely viral weapon into a tunable tool. By dialing integration activity up or down through targeted mutations, researchers can design vectors that match the clinical need, permanent insertion when durability matters, episomal expression when safety from insertional mutagenesis is the priority.
How the Field Got Here
The concept of integrated retroviral DNA traces back to Howard Temin’s provirus hypothesis in 1964, years before the enzymes responsible were identified.25PubMed Central. Retroviral Integrase: Then and Now It took two more decades of biochemistry and molecular biology before integrase was purified, its activities reconstituted in test tubes, and its structure solved domain by domain. The HIV epidemic accelerated the pace dramatically: the need for new drug targets gave integrase research an urgency that led to the approval of the first INSTI, raltegravir, in 2007. Since then, integrase inhibitors have become the backbone of first-line HIV regimens worldwide. High-resolution cryo-electron microscopy structures of full intasomes, solved from roughly 2017 onward, finally showed how integrase assembles on viral DNA and engages the host chromosome in atomic detail, answering structural questions that had lingered for decades.26PubMed Central. Brief Histories of Retroviral Integration Research and Associated International Conferences